Precigen (NASDAQ:PGEN) Shares Down 9% - Time to Sell?
Precigen (NASDAQ:PGEN) shares dropped 9% on Monday, trading at $3.3390 with significantly lower than average volume. Despite beating EPS estimates, the company missed revenue expectations and has a negative net margin. Analysts currently have a "Hold" consensus rating with an average price target of $9.50, and institutional investors have recently adjusted their holdings.
[144] PRECIGEN, INC. SEC Filing
Precigen, Inc. (NASDAQ: PGEN) has filed a Form 144 with the SEC, notifying the market of proposed sales of Common Stock by affiliates. The filing details historical issuances and transfer events from 2013 to 2018, including private placements, RSU vesting, and a secondary public offering. This procedural filing documents past share transactions but does not specify the exact amount or timing of current proposed resale for cash-flow details.
Precigen to Participate in a Fireside Chat with H.C. Wainwright on March 31
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company, announced that its President and CEO, Helen Sabzevari, PhD, and Chief Commercial Officer, Phil Tennant, will participate in a virtual fireside chat with H.C. Wainwright on March 31, 2026, from 11:00 AM – 12:00 PM ET. The event details will be available on Precigen's website. The company specializes in advancing innovative precision medicines for difficult-to-treat diseases in immuno-oncology, autoimmune disorders, and infectious diseases.
Precigen to Participate in a Fireside Chat with H.C. Wainwright on March 31
Precigen, Inc.'s President and CEO, Helen Sabzevari, and Chief Commercial Officer, Phil Tennant, will participate in a virtual fireside chat with H.C. Wainwright on March 31, 2026, from 11:00 AM – 12:00 PM ET. The commercial-stage biopharmaceutical company specializes in advancing innovative precision medicines for difficult-to-treat diseases. Details for viewing the event can be found on Precigen's investor relations website.
Precigen (PGEN) Is Up 11.9% After PAPZIMEOS’ Launch Shifts Focus Toward Commercial Revenue Model
Precigen (PGEN) saw its stock increase by 11.9% following the launch of its FDA-approved therapy, PAPZIMEOS, which signifies a strategic shift towards a commercial revenue model. Despite reporting widening net losses in 2025 (US$250.64 million), a significant increase in revenue to US$9.68 million was noted. The upcoming permanent J-code for PAPZIMEOS on April 1, 2026, is expected to streamline billing and improve reimbursement, which is crucial for the company's financial stability and achieving cash flow breakeven amidst growing operating costs.
Precigen (NASDAQ:PGEN) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen upgraded Precigen (NASDAQ:PGEN) from a "sell" to a "hold" rating, contributing to a consensus "Hold" rating and a $9.50 target price, bolstered by other analysts raising price targets. The biotechnology company reported a Q4 EPS beat but missed on revenue, though management anticipates accelerating PAPZIMEOS launch with Q1 revenue exceeding $18M and potential cash-flow breakeven in 2026. Despite a 145% one-year surge and institutional interest, concerns about valuation and high trading volume suggest near-term pullback risk for the stock.
Precigen's $430M Burn vs $18M Q1 Bet: Why Wall Street's $8.50 Target Risks a Reality Check
Precigen (PGEN) reported full-year 2025 revenue of $9.7 million, a 149% increase, primarily due to the launch of Papzimeos in November 2025, with Q1 2026 revenue projected to exceed $18 million. Despite this revenue growth, the company posted a net loss of $429.6 million, driven by significant selling, general, and administrative expenses related to commercialization. Wall Street's bullish $8.50 price target implies a high-risk, high-reward scenario, dependent on the company's ability to sustain rapid commercial growth and manage its substantial cash burn.
Precigen’s first FDA-approved RRP drug starts selling as access expands
Precigen reported its full-year 2025 financial results, marking its transition to a commercial-stage company following the FDA approval of PAPZIMEOS in August 2025. The drug generated $3.4 million in product revenue and expanded patient access significantly with a J-code assignment and broad payer coverage. Despite a net loss, the company anticipates funding operations to cash-flow break-even by the end of 2026, driven by PAPZIMEOS sales.
These Analysts Boost Their Forecasts On Precigen Following Q4 Results
Following Precigen Inc.'s mixed Q4 results, where the company beat earnings estimates but missed on sales, two analysts raised their price targets. HC Wainwright & Co. increased its price target from $9 to $10, maintaining a Buy rating, while Citizens analyst Jason N. Butler raised his target from $8 to $9, keeping a Market Outperform rating. The company's CEO highlighted the transformational year with the FDA approval and launch of PAPZIMEOS.
Precigen, Inc. (NASDAQ:PGEN) Q4 2025 Earnings Call Transcript
Precigen, Inc. (NASDAQ:PGEN) held its Q4 2025 earnings call, discussing the successful commercial launch of their drug Papzimia for Recurrent Respiratory Papillomatosis (RRP). The company reported Q4 2025 net product revenue of $3.4 million and projected Q1 2026 revenues to exceed $18 million, indicating strong uptake and expanded payer coverage. Precigen also highlighted progress in payer coverage, patient enrollment, and plans for a pediatric RRP clinical trial and European market expansion for Papzimia, alongside updates on their PRGN-2009 program for HPV-associated cancers.
H.C. Wainwright raises Precigen stock price target on sales growth
H.C. Wainwright has increased its price target for Precigen Inc. (NASDAQ:PGEN) to $10 from $9, maintaining a Buy rating, citing strong sales growth, particularly for its product Papzimeos. The company reported $3.4 million in Q4 2025 sales and anticipates over $18 million in Q1 2026, supported by commercial momentum and a permanent J-code taking effect soon. Analysts project significant sales growth for the current year, with H.C. Wainwright forecasting $113 million for fiscal year 2026.
Citizens raises Precigen stock price target on strong PAPZIMEOS sales
Citizens increased its price target for Precigen (NASDAQ:PGEN) to $9.00 from $8.00, maintaining a Market Outperform rating, due to strong sales of PAPZIMEOS for recurrent respiratory papillomatosis. The company's fourth-quarter 2025 results showed a revenue surge and management expects first-quarter 2026 PAPZIMEOS sales to exceed $18 million. Despite a net loss, Precigen's financial outlook is supported by sufficient funding and impressive commercial metrics for its leading drug.
Precigen, Inc. (PGEN) reports Q4 loss, lags revenue estimates
Precigen, Inc. (PGEN) reported a loss for the fourth quarter, failing to meet revenue expectations. The life sciences company's Q4 loss was $0.16 per share, slightly worse than analysts' predicted loss of $0.15 per share. Revenue for the quarter reached $16.89 million, falling short of the $27.09 million forecast by analysts.
Precigen, Inc. (PGEN) Posts Fourth Quarter Loss, Misses Revenue Expectations
Precigen, Inc. (PGEN) reported a smaller-than-expected loss of $0.01 per share for the fourth quarter of 2025, significantly outperforming the Zacks Consensus Estimate of a $0.10 loss. However, the company missed revenue expectations, generating $4.57 million against an estimate of $5.53 million. Despite a positive earnings surprise, Precigen's stock has declined by 25.1% year-to-date, and its future performance will likely depend on management insights and evolving analyst estimates.
Precigen 10-K: $9.68M Revenue, $(1.37) EPS on FY net loss
Precigen (PGEN) reported total revenues of $9.684 million for the year, a significant increase driven by the launch of Papzimeos and Exemplar services. Despite improved operating loss due to lower expenses and strategic pipeline reprioritization, the company recorded a full-year net loss of $(250.642) million, leading to a net loss per share of $(1.37), primarily due to other expense fair value changes. This financial performance reflects Precigen's transition to commercial operations following the FDA approval of Papzimeos.
Precigen reports $9.7M revenue, $110.5M operating loss and $429.6M net loss to common in 2025
Precigen reported $9.7 million in revenue for 2025, driven by initial commercial sales of PAPZIMEOS and licensing income. The company incurred an operating loss of $110.5 million and a net loss of $429.6 million attributable to common shareholders. Despite the losses, Precigen ended the year with $100.4 million in cash and expects these funds to support operations to cash flow break-even, following key business achievements like FDA approval and commercial launch of PAPZIMEOS.
Precigen (NASDAQ:PGEN) Issues Earnings Results, Beats Expectations By $0.09 EPS
Precigen (NASDAQ:PGEN) reported earnings per share of ($0.01), surpassing the consensus estimate by $0.09, though revenue at $4.57 million missed analyst expectations of $8.29 million. Despite beating EPS, shares traded down about 1% to $3.10, resulting in a market capitalization of $1.10 billion and a negative P/E ratio. The financial picture shows a remarkably high return on equity of 1,066.10% but also a deeply negative net margin of 3,912.92%.
Precigen Insiders Sold US$7.6m Of Shares Suggesting Hesitancy
Over the past year, insiders at Precigen, Inc. sold US$7.6 million worth of shares, significantly more than the US$236k they bought. The largest sale was made by Executive Chairman Randal Kirk for US$6.2 million at a price close to the current share price, which analysts suggest could be a red flag for investors. Despite this selling, insiders still retain a substantial 13% ownership in the company, valued at US$146 million.
Precigen (NASDAQ:PGEN) Stock Crosses Below Two Hundred Day Moving Average - Time to Sell?
Precigen (NASDAQ:PGEN) stock recently fell below its 200-day moving average, trading at $3.24 against a $3.99 average. The company, which is currently loss-making with a market cap of $1.15 billion, has a consensus "Hold" rating from Wall Street analysts with an average target price of $8.50. Institutional investors own about 33.5% of the biotechnology company, which focuses on genetic medicines.
PRECIGEN (PGEN) Chief Legal Officer converts 40,443 RSUs into common stock
PRECIGEN's Chief Legal Officer, Donald P. Lehr, has converted 40,443 Restricted Stock Units (RSUs) into common stock. This transaction, filed on March 18, 2026, was a routine equity compensation event where the RSUs vested immediately and were subsequently exercised into shares, increasing his direct holdings to 722,092 shares. The filing indicates this was not an open-market purchase or sale.
Precigen (PGEN) COO receives 44,495 RSUs that vest into shares
Precigen's (PGEN) Chief Operating Officer, Rutul R. Shah, was granted 44,495 Restricted Stock Units (RSUs) on March 18, 2026. These RSUs vested immediately and were converted into 44,495 shares of common stock at a price of $0.00 per unit. Following this transaction, Shah's direct holding of Precigen common stock increased to 450,454 shares.
Precigen (PGEN) CCO granted 42,110 RSUs that vest immediately and convert to stock
Precigen's Chief Commercial Officer, Phil Tennant, was granted 42,110 restricted stock units (RSUs) on March 18, 2026. These RSUs vested immediately and converted into common stock, increasing his direct holdings to 107,141 shares. This transaction was compensation-related equity award and not an open-market purchase or sale.
Precigen (NASDAQ: PGEN) CEO nets 321,100 shares from RSUs
Precigen's CEO, Helen Sabzevari, received a grant of 321,100 restricted stock units (RSUs) on March 18, 2026, which vested immediately and were then exercised into 321,100 shares of common stock at $0.00 per unit. These compensation-related transactions increased her direct holdings to 3,638,122 shares of Precigen common stock. The Form 4 filing clarifies that these were not open-market purchases.
PRECIGEN (PGEN) CFO receives 40,293 RSUs and converts them into common stock
PRECIGEN's CFO, Harry Thomasian Jr., was granted 40,293 restricted stock units (RSUs) on March 18, 2026, which immediately vested. He subsequently converted these RSUs into 40,293 shares of common stock at a conversion price of $0.00 per share. This transaction increased his direct holdings of PRECIGEN common stock to 508,919 shares.
Precigen Stock Hits Day Low of $3.94 Amid Price Pressure
Precigen, Inc. (PGEN) experienced a significant intraday stock price decline of 9.13%, hitting a low of $3.94. This comes despite a strong annual performance, as year-to-date figures show a decrease, and long-term prospects are concerning due to declining net sales and negative financial metrics. The company's market capitalization is $1,577 million, and its trading dynamics suggest heightened risk.
Precigen, Inc. Hits Day Low of $3.27 Amid Price Pressure
Precigen, Inc. experienced a significant stock price decline, hitting an intraday low of $3.27, reflecting a challenging trading environment. The company has struggled with consistent growth, evident in a 42.55% annual decline in net sales over five years and negative financial metrics like a -233.25% return on equity. Despite a 95.81% annual performance, year-to-date results show a 21.77% downturn, indicating ongoing volatility.
Director Frank Steven converts 71,839 RSUs into Precigen (PGEN) common stock
Precigen (PGEN) director Frank Steven converted 71,839 restricted stock units (RSUs) into an equal number of common shares on March 13, 2026. This transaction increased his direct holdings to 1,226,391 common shares, reflecting equity compensation rather than an open-market purchase. The conversion was reported in a Form 4 SEC filing.
[Form 4] PRECIGEN, INC. Insider Trading Activity
PRECIGEN, INC. director Vinita D. Gupta reported the vesting and exercise of 71,839 restricted stock units (RSUs) into common shares on March 13, 2026. This transaction was compensation-related, with no exercise price, and increased her direct holdings to 666,027 shares of Precigen common stock. The filing confirms this was not an open-market purchase or sale.
Precigen (PGEN) director converts 71,839 RSUs into common stock, now holding 305,776 shares
Precigen director Nancy H. Agee converted 71,839 Restricted Stock Units (RSUs) into common shares on March 13, 2026, increasing her direct holdings to 305,776 shares. This transaction was a compensation-related equity vesting, not an open-market purchase or sale. The SEC Form 4 filing details this change in beneficial ownership.
Precigen (PGEN) insider exercises 143,678 RSUs into common stock
Precigen director Randal J. Kirk exercised 143,678 restricted stock units (RSUs) into common stock on March 13, 2026, at an exercise price of $0.00 per share. These shares are indirectly held through the R.J. Kirk Declaration of Trust, which now owns over 81 million shares of Precigen common stock, with beneficial ownership disclaimed except for pecuniary interest. The RSUs were granted on March 13, 2025, and vested fully on their one-year anniversary.
Precigen (PGEN) director exercises RSUs, adds 71,839 common shares
Precigen, Inc. director Fred Hassan exercised restricted stock units (RSUs), converting 71,839 units into an equal number of common shares on March 13, 2026. These RSUs vested in full at an exercise price of $0.00 per share, increasing Hassan's direct ownership to 1,243,239 shares of Precigen common stock. This transaction was a derivative exercise and did not involve open-market purchases or sales.
RSU vesting gives Precigen (PGEN) director 71839 new common shares
Precigen director Jeffrey B. Kindler received 71,839 common shares through the vesting of restricted stock units (RSUs) on March 13, 2026. This transaction increased his direct holdings to 202,100 shares of Precigen common stock, with no open-market purchases or sales reported. The RSU vesting is part of his equity compensation, aligning his incentives with the company's performance.
Precigen, Inc. Hits Day High with Strong 7.01% Intraday Surge
Precigen, Inc. (PGEN) experienced a significant intraday surge of 7.01%, reaching a high of USD 3.55. While the stock has outperformed the S&P 500 over the past year with a 101.72% return, its year-to-date performance shows a decline of 16.03%. Despite short-term gains, the company faces long-term challenges, including declining net sales and concerning financial metrics like negative return on equity and debt-to-equity ratios.
Cantor Fitzgerald Reaffirms Overweight Rating on Precigen (PGEN)
Cantor Fitzgerald has reaffirmed its "Overweight" rating on Precigen (PGEN). The report indicates a continued positive outlook on the company's stock by the analyst firm. This reaffirmation suggests confidence in Precigen's future performance.
Is Precigen (PGEN) Reflecting Its Recent Surge Despite Steep Short Term Pullback
This article analyzes Precigen (PGEN) to determine if its current share price reflects its underlying value, considering its recent significant stock movements. Using a Discounted Cash Flow (DCF) analysis, the article concludes that PGEN is significantly overvalued by 293.6% compared to its estimated intrinsic value. Additionally, its Price-to-Book (P/B) ratio of 27.72x is well above industry and peer averages, further suggesting overvaluation for the biotech company.
Director at Precigen (NASDAQ: PGEN) granted stock, RSUs and options
Precigen director Fred Hassan received new equity awards, including 35,612 restricted stock units and an option for 41,073 shares of common stock at $3.51 per share, both dated March 10, 2026. He also received 17,948 shares of common stock in lieu of an annual cash retainer. Following these transactions, Hassan directly owns 1,171,400 shares of Precigen common stock.
Is Precigen (PGEN) Reflecting Its Recent Surge Despite Steep Short Term Pullback
Precigen (PGEN) has experienced significant stock price movements, including an 88.5% return over one year and a 203.7% return over three years, despite recent short-term declines. A Discounted Cash Flow (DCF) analysis suggests the stock is 293.6% overvalued, with an estimated intrinsic value of $0.83 per share compared to its $3.28 closing price. The company's Price-to-Book (P/B) ratio of 27.72x is also considerably higher than the biotech industry and peer averages, indicating a potentially high market valuation.
PRECIGEN (PGEN) director granted RSUs, stock options and shares as compensation
PRECIGEN (PGEN) director James S. Turley received RSU's, stock options, and common stock as compensation, rather than through open-market trades. On March 10, 2026, Turley was granted 35,612 restricted stock units, options for 41,073 shares at $3.51 per share, and 17,806 shares of common stock in lieu of a $62,500 cash retainer. These transactions increased his direct common stock holdings to 613,578 shares, and the RSUs are set to vest on March 10, 2027.
PRECIGEN (PGEN) director Vinita Gupta receives RSUs, stock options and shares
PRECIGEN director Vinita D. Gupta received equity awards as compensation, including 35,612 restricted stock units vesting in March 2027, and options to purchase 41,073 shares at an exercise price of $3.51, expiring in March 2036. She also acquired 17,948 common shares in lieu of a $63,000 cash retainer, increasing her direct holdings to 594,188 shares. This aligns her compensation with the company's future performance.
Precigen (NASDAQ:PGEN) Upgraded at Zacks Research
Zacks Research has upgraded Precigen (NASDAQ:PGEN) from a "strong sell" to a "hold" rating, contributing to a consensus "Hold" rating among analysts with an average price target of $8.50. The stock recently opened at $3.42 and has a market capitalization of $1.21 billion. Notably, Director Randal J. Kirk sold a significant number of shares, reducing his holding, while institutional investors like Patient Capital Management LLC increased their stakes.
Precigen to Announce Full Year 2025 Financial Results
Precigen, a biopharmaceutical company, announced that it will release its full year 2025 financial results and provide business updates on Wednesday, March 25, 2026. This announcement is significant for investors and the healthcare industry as it will offer insights into the company's progress in precision medicine and commercialization efforts. The company will also host a conference call on the same day at 4:30 PM ET to discuss the results.
Precigen to Announce Full Year 2025 Financial Results and Provide Business Updates on March 25
Precigen, Inc. (Nasdaq: PGEN) announced it will release its full year 2025 financial results and provide business updates on Wednesday, March 25, 2026. The company will host a conference call on that day at 4:30 PM ET to discuss the results. Precigen is a commercial-stage biopharmaceutical company focused on developing precision medicines for difficult-to-treat diseases.
Biotech firm Precigen schedules March 25 call on 2025 results
Precigen (Nasdaq: PGEN) announced it will release its full-year 2025 financial results and provide business updates on Wednesday, March 25, 2026. The company will host a conference call at 4:30 PM ET to discuss these results, with dial-in details provided for both North American and international participants. Historically, similar earnings date notices for PGEN have shown limited immediate market impact.
Precigen to Announce Full Year 2025 Financial Results and Provide Business Updates on March 25
Precigen, Inc. announced its plan to release full-year 2025 financial results and provide business updates on Wednesday, March 25, 2026. The company will host a conference call on the same day at 4:30 PM ET to discuss the results. Precigen is a commercial-stage biopharmaceutical company focused on precision medicines for various diseases including immuno-oncology, autoimmune disorders, and infectious diseases.
Precigen to Announce Full Year 2025 Financial Results and Provide Business Updates on March 25
Precigen, Inc. announced it will release its full-year 2025 financial results and provide business updates on Wednesday, March 25, 2026. The company will host a conference call on the same day at 4:30 PM ET to discuss the results. Precigen is a commercial-stage biopharmaceutical company focused on developing precision medicines for difficult-to-treat diseases.
Precigen, Inc. (NASDAQ:PGEN) Given Average Rating of "Hold" by Brokerages
Precigen, Inc. (NASDAQ:PGEN) has received an average "Hold" rating from brokerages, with an average 12-month price target of $8.50. Recent analyst reports show a mixed sentiment, with some downgrades and one price target boost with a "buy" rating. Insider transactions reveal Director Randal J. Kirk sold a significant number of shares, while institutional investors like Patient Capital Management and State Street Corp have increased their holdings.
A Look At Precigen (PGEN) Valuation After Mixed Quarterly Earnings And Revenue Surprise
Precigen (PGEN) reported mixed quarterly results with revenue exceeding expectations but EPS falling short, leading to questions about its current valuation. Despite recent short-term stock declines, the company has shown strong long-term shareholder returns. The article discusses Precigen's valuation, noting it's considered 60.9% undervalued according to a popular narrative but trades at a high P/B ratio, indicating market optimism about future growth.
Precigen earnings in focus as gene therapy revenue ramps up
Precigen is set to report fourth-quarter results, with analysts focusing on the revenue growth driven by its FDA-approved gene therapy, PAPZIMEOS. Investors will be monitoring patient enrollment conversion into revenue, the company's path to profitability, and updates on the European market for PAPZIMEOS. The stock previously saw a significant climb due to FDA approval but has recently pulled back, making this earnings report crucial for evaluating its commercial promise.
Why Precigen (PGEN) Is Down 11.5% After Mixed Quarterly Results And What's Next
Precigen (PGEN) saw an 11.5% drop after mixed quarterly results, with revenue surprising positively but EPS falling short. The company's future hinges on the successful launch and scaling of its therapy, PAPZIMEOS, for recurrent respiratory papillomatosis, despite significant funding and dilution risks. Analysts are focusing on the top-line growth trajectory, yet investor opinions on its fair value range widely, reflecting the uncertainty surrounding its key product's uptake.
Why Precigen (PGEN) Is Down 11.5% After Mixed Quarterly Results And What's Next
Precigen (PGEN) recently reported mixed quarterly results, with revenue exceeding expectations but earnings per share falling short. The focus remains on the commercial launch of PAPZIMEOS and its potential to scale, reinforcing the company's long-term gene and cell therapy pipeline. Despite the earnings miss, analysts are optimistic about revenue expansion, valuing the stock with a significant upside, reflecting varied market perspectives on its future performance.
